Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Monday, February 9, 2015

Hopes for single-dose Hepatitis C drug fade

Shares of Regulus fall but company, analysts still see promise 

LOS ANGELES (MarketWatch) — Shares of Regulus Therapeutics took it on the chin Monday after the biopharmaceutical company reported spotty results in tests for a drug designed to cure Hepatitis C with a single dose.

Regulus RGLS, +1.55%  shares dropped 10% to $15.15, as it appeared its drug, now designated as RG-101, will have to be accompanied by other treatments in many patients in order to cure Hepatitis C.

The company said RG-101 appeared to wipe out traces of the disease in four of 14 patients with a 2-milligram dose. This test was critical because it showed the drug’s ability to keep Hepatitis C at bay for 85 days. Patients who show no signs of Hepatitis C after 84 days are considered cured. 

Read more...
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)